Tumour incidences and multiplicity in the different treatment groups
| Group | Treatment | No of deaths (%) | No of rats with gastric tumours (%) (incidence)* | No of gastric cancers per rat (SD) (multiplicity)† |
|---|---|---|---|---|
| *p = 0.002 (χ2): C versus B, p = 1.00; D versus B, p = 1.00; E versus B, p = 0.004; F versus B, p = 0.052. | ||||
| †p = 0.001 (ANOVA): C versus B, p = 1.00; D versus B, p = 1.00; E versus B, p = 0.004; F versus B, p = 0.025. | ||||
| A | Control | 0 (0) | 0 (0) | 0 (0) |
| B | MNNG alone | 6 (37.5) | 12 (75.0) | 1.0 (0.7) |
| C | MNNG+indomethacin | 6 (37.5) | 11 (68.8) | 0.8 (0.80 |
| D | MNNG+celecoxib 5 mg/kg/day | 5 (29.4) | 12 (70.6) | 0.8 (0.6) |
| E | MNNG+celecoxib 10 mg/kg/day | 6 (37.5) | 3 (18.8) | 0.2 (0.4) |
| F | MNNG+celecoxib 20 mg/kg/day | 3 (18.8) | 5 (31.3) | 0.3 (0.5) |